Overview: Tissue Transglutaminase IgA Reflex Anti-Endomysial IgA TestIntroduction: The Tissue Transglutaminase IgA Reflex Anti-Endomysial IgA Test detects tTG IgA with reflex to endomysial IgA to confirm celiac disease, causing diarrhea or abdominal pain. Aligned with 2023 AGA guidelines, it uses immunoassays for high specificity, supporting autoimmune screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected celiac disease. Note: No specific test parameters provided in input data.
Other Names: tTG Reflex Assay, tTG-Endomysial IgA Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: tTG reflex testing began in the 2000s with celiac research. Immunoassay methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects tTG IgA with reflex to endomysial IgA to confirm celiac disease, guides treatment, and evaluates patients with diarrhea or abdominal pain.
Test Parameters: Not specified in input data; typically includes tTG IgA and endomysial IgA antibodies.
Pretest Condition: No fasting required. Collect serum or saliva. Report history of diarrhea, abdominal pain, or gastrointestinal symptoms.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document diarrhea, abdominal pain, or history of celiac disease. Include current medications, especially gluten exposure.
Consent: Written consent required, detailing the tests purpose, celiac disease implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) for tTG IgA, with reflex to immunofluorescence for endomysial IgA if positive. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for celiac disease confirmation.
Factors Affecting Result Accuracy: Sample hemolysis or IgA deficiency can affect results. Gluten-free diet may cause false negatives.
Clinical Significance: Positive tTG IgA and endomysial IgA confirm celiac disease, guiding gluten-free diet. Negative results may require biopsy or tTG IgG testing.
Specialist Consultation: Consult a gastroenterologist for result interpretation and treatment planning.
Additional Supporting Tests: tTG IgG, small bowel biopsy, or HLA-DQ typing to confirm celiac disease diagnosis.
Test Limitations: Non-specific in IgA deficiency; clinical correlation is needed. Sample quality affects sensitivity.
References: AGA Celiac Disease Guidelines, 2023; Gastroenterology, Lebwohl B, 2022.
